Allergy Immunotherapy Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Japan, China, India, Australia, Mexico, Brazil, Argentina, South Africa, GCC Countries), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025
Report ID: GMI4298
Allergy immunotherapy market size is expected to grow significantly from 2019 to 2025.
The allergy immunotherapy market is anticipated to grow at a remarkable pace, which can be attributed to the growing consciousness of patients about the allergy treatment, development of novel products, and an increasing number of allergic patients. After the FDA approval of Sublingual immunotherapy (SLIT) tablets, allergy immunotherapy gained popularity to treat grass pollen as well as ragweed allergies. The introduction of such therapies is expected to reduce the symptoms of allergy by increasing the tolerance of the allergy effects.
Furthermore, the growing awareness of allergies among the general population is expected to be a prominent revenue enabler. According to the World Allergy Organization (WAO), a notable rise in the prevalence of allergies has been observed in recent years. Allergic rhinitis is one of the prevalent disorder that has a significant impact on the quality of several patient’s life. As a subsequence to the awareness created by numerous health organizations, governments of many countries have sanctioned budget for the research and development of allergy immunotherapy as an effective cure. This is one of the major factors, which is expected to reflect considerably on the market size of the allergy immunotherapy market. However, the allergy immunotherapy tablets are capable to cure only a specific type of allergen and remain incompetent to prevent the development of new allergies.
Subcutaneous Immunotherapy Treatment (SCIT) segment marked a significant revenue share in 2018 and is projected to witness significant growth during the forthcoming years. This is majorly due to the SCIT is the traditional method of allergy immunology with a clinical history of over 100 years. Whereas, Sublingual Immunotherapy Treatment (SLIT) is a more modern form of immunology treatment, and it has become increasingly popular in recent years. SCIT is also known as allergy shots that generally provides relief for more than one allergen, while SLIT treatments are restricted to a single allergen. Besides this, with the endorsement from the World Health Organization (WHO), the Cochrane Collaboration & over 60 double-blind trials proving efficacy and safety, SLIT gained recognition as an effective treatment option. However, dearth of awareness and lack of willingness to accept new treatment therapies reduces the adoption of SLIT in emerging regions. This factor increased the adoption of SCIT among the general population.
Hospital pharmacies are expected to register a noteworthy revenue share in the allergy immunology market due to the easy accessibility of hospital pharmacies to the patients while taking treatments from hospitals. Moreover, hospital pharmacies are very well connected with the distributors. The above-mentioned factors will escalate the usage of allergy immunotherapy in hospital pharmacies, thereby contributing to segment growth.
North America allergy immunotherapy market is anticipated to grow significantly over the coming years. Factors like the presence of notable industry players, well-established healthcare infrastructure, increasing the developing of novel treatments along with growing healthcare expenditure augments the business growth in the North America region. Moreover, the growing prevalence of asthma, the rise in many allergies due to alarming pollution levels and awareness campaigns will drive the overall industry market growth. For instance, the Asthma and Allergy Foundation of America (AAFA), is one the leading non-profit patient organization for people with allergies and asthma.
Some of the major notable players operating in the allergy immunotherapy include ALK-Abello, Stallergenes Greer, HAL Allergy Group, Allergy Therapeutics, DBV Technologies, Merck KGaA, Anergis, Aimmune Therapeutics, Circassia, and Biomay AG. Companies are majorly focusing on obtaining FDA and marketing approval of new products in the allergy immunotherapy market. For instance, in June 2019, ALK-Abello obtains the European approval for tree sublingual allergy immunotherapy tablets in 17 European countries. Itulazax is anticipated to be the brand name of the tree SLIT-tablet. On November 11, 2018, Stallergenes Greer received FDA approval for the extension of indication for Oralair. The tablet is used to treat patients of age group between five to nine with grass pollen-induced allergic rhinitis.
Allergy Immunotherapy Market By Treatment Type, 2014-2025 (USD Million)
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy(SLIT)
Allergy Immunotherapy Market By Allergy Type, 2014-2025 (USD Million)
- Allergic Rhinitis
- Food Allergy
Allergy Immunotherapy Market By Distribution channel, 2014-2025 (USD Million)
- Hospital pharmacies
- Retail pharmacies
- Drug stores
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- GCC Countries
- ALK-Abello A/S
- Stallergenes Greer
- HAL Allergy Group
- Allergy Therapeutics
- DBV Technologies
- Merck Kya
- Aimmune Therapeutics
- Biomay AG
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability